A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors.

被引：0
|
作者：
Plummer, R
Vidal, L
Perrett, R
Shaw, H
Pilkington, M
Hanwell, J
Temple, G
Fong, P
Amelsberg, A
Calvert, H
de Bono, J
机构：
[1] No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[2] Royal Marsden Hosp, London SW3 6JJ, England
[3] Boehringer Ingelheim, Bracknell, Berks, England
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：8990S / 8990S
页数：1
相关论文
共 50 条
  • [41] BIBW 2992, an irreversible dual EGFR/HER2 kinase inhibitor, shows activity on L858R/T790M EGFR mutants.
    Solca, F
    Schweifer, N
    Baum, A
    Rudolph, D
    Amelsberg, A
    Himmelsbach, F
    Beug, H
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9025S - 9025S
  • [42] A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
    Zhang, Pin
    Wang, Lin
    Zhen, Yueying
    Wang, Zhihong
    Zhang, Hesheng
    Jones, Richard
    Xu, Binghe
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (01)
  • [43] Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
    Kim, Tae Min
    Lee, Keun-Wook
    Oh, Do-Youn
    Lee, Jong-Seok
    Im, Seock-Ah
    Kim, Dong-Wan
    Han, Sae-Won
    Kim, Yu Jung
    Kim, Tae-You
    Kim, Jee Hyun
    Han, Hyesun
    Kim, Woo Ho
    Bang, Yung-Jue
    CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 835 - 842
  • [44] Growth response of human colorectal tumour cell lines to treatment with BIBW2992, an irreversible EGFR/HER1 and HER-2 tyrosine kinase inhibitor
    Khelwatty, S.
    Essapen, S.
    Seddon, A. M.
    Modjtahedi, H.
    EJC SUPPLEMENTS, 2010, 8 (07): : 51 - 51
  • [45] BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor for the Treatment of Patients with HER2-Negative Metastatic Breast Cancer after Failure of No More Than Two Prior Chemotherapies
    Harbeck, N.
    Schmidt, M.
    Harter, P.
    Possinger, K.
    Jonat, W.
    Lueck, H.-J.
    Beckmann, M.
    Fasching, P.
    Schuette, J.
    Solca, F.
    Uttenreuther-Fischer, M.
    Taton, M.
    Lahogue, A.
    Awada, A.
    De Greve, J.
    Canon, J. L.
    Dirix, L.
    Fleischer, F.
    Neven, P.
    Gottschalk, N.
    Piccart, M.
    Schuler, M.
    CANCER RESEARCH, 2009, 69 (24) : 785S - 786S
  • [46] ACTIVITY OF BIBW 2992, AN IRREVERSIBLE EGFR/HER1 AND HER2 TKI, IN LUNG ADENOCARCINOMA PATIENTS HARBORING LESS COMMON EGFR MUTATIONS
    Shih, J.
    Yu, C.
    Su, W.
    Hsia, T.
    Graziano, S. L.
    Calvo, R.
    Cong, X. J.
    Shahidi, M.
    Yang, C.
    Miller, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 138 - 138
  • [47] A population pharmacokinetic analysis of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors.
    Guo, F
    Letrent, SP
    Sharma, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P54 - P54
  • [48] BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies
    Schuler, M. H.
    Uttenreuther-Fischer, M. M.
    Piccart-Gebhart, M. J.
    Harbeck, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] A phase 1 study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours
    Cresti, N.
    Jodrell, D.
    Arkenau, T.
    Forster, M.
    Donaldson, K.
    Posner, J.
    Kawabata, I.
    Plummer, R.
    Spicer, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S160 - S161
  • [50] Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR
    Spicer, James
    Calvert, Hilary
    Vidal, Laura
    Azribi, Fathi
    Perrett, Rebecca
    Shahidi, Mehdi
    Temple, Graham
    Futreal, Andrew
    De Bono, Johann
    Plummer, Ruth
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S410 - S410
12345